The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
the incidence of side effects was really hardly different at all between the the different everolimus groups and the placebo and particularly the five mig once a week there really was no significant increase in adverse events in that group
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
the other thing though that I think was super important about that paper was it was pretty large I mean not huge it wasn't like a phase three but there were yes 3 if I'm yeah I think it was about 80 per arm okay so hundreds of people in this study who got ever alus who didn't have an organ transplant and weren't taking other immunosuppressants and the side effect profile at least in the five migs once a week group was essentially no different than Placebo